Bristol Myers Squibb (NYSE: BMY) reported positive interim Phase 3 results from its SUCCESSOR-2 study of oral mezigdomide in patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE